



October 30, 2026

Company name: SanBio Co., Ltd.
(Code: 4592 TSE Growth)
Name of Representative: Keita Mori, Representative Director and President
For inquiries, contact: Yoshihiro Kakutani, Corporate Officer of Management Administration
(Phone: 03-6264-3481)

**Notice Regarding Conclusion of a Committed Credit Line Agreement
with Resona Bank, Limited and Expansion of Borrowing Facility**

SanBio Co., Ltd. (head office: Tokyo, Japan; Representative Director and President: Keita Mori; hereinafter “SanBio” or the “Company”) hereby announces that it has entered into a new committed credit line agreement with Resona Bank, Limited, replacing its existing agreement, and has expanded its borrowing facility from 1 billion yen to 5 billion yen.

In July 2024, SanBio obtained conditional and time-limited approval for AKUUGO® Suspension for Intracranial Implantation (“AKUUGO®”), and began sales of the product in May 2026. The Company has primarily focused on research and development to date. With this launch, it will continue to center its business on expanding into new regions and adding new indications through R&D, while also taking on the manufacturing and sale of its products.

This agreement expands SanBio’s borrowing facility to meet the working capital needs of AKUUGO® sales in Japan, covering the period between paying manufacturing costs and collecting sales proceeds. By funding this working capital through borrowing, the Company can direct the capital it has raised to date, including through share issuances, toward investment for future growth. This agreement also gives the Company more flexible and stable access to funding, strengthening the financial foundation that supports its business expansion.

Overview of the agreement with Resona Bank, Limited concluded today

Financing type	Contract amount	Agreement date	Expiration date	Use of funds
Committed credit line	5 billion yen	October 30, 2026	October 30, 2028	Working capital for AKUUGO® sales in Japan

The existing committed credit line agreement concluded on March 31, 2025 (borrowing facility: 1 billion yen) was terminated today upon conclusion of this agreement.

This matter will have only a minimal impact on the consolidated earnings forecast for the fiscal year ending January 2027.